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CObjectives: The purpose of this systematic review is primarily to iden-
tify published cost-effectiveness analyses and cost-utility analyses of
endocrine therapies for the treatment of early breast cancer. A second-
ary objective is to identify whether differences in sevenmodeling char-
acteristics are related to differences in outcome of these cost-effective-
ness and cost-utility analyses. Methods: A systematic literature
eview was conducted to identify peer-reviewed full economic evalua-
ions of endocrine treatments of early breast cancer published in the
nglish language between 2000 and December 2010. Information from
hese publications was abstracted regarding outcome, quality, and
odeling methods. Results: We identified 20 economic evaluations
omprising 5 different endocrine therapeutic strategies, which are all
ssessed more then once. The incremental cost-effectiveness ratios
ICERs) of the reported outcomes varied widely for identical therapies.
or anastrazole compared to tamoxifen, incremental life-years gained
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oi:10.1016/j.jval.2011.08.00375,331. Incremental quality-adjusted life-years (QALYs) gained ranged
rom 0.092 to 0.378 with a cost per QALY gained varying from €3,696 to
120,265. These large differences in outcome were related to different
odeling methods, with differences in time horizon and use of a car-
yover effect as most prominent causes. Conclusion: Despite similar
omparators and logical differences due to transferability issues, the
utcomes of the included studies varied widely. To increase compara-
ility and transparency of pharmacoeconomic evaluations, standard-
zation of modeling methods for different therapeutic groups/diseases
nd the availability of a detailed and complete description of themodel
sed in the evaluation is advocated. Recommendations for standard-
zation inmodeling treatment strategies in early breast cancer are pre-
ented.
eywords: economic evaluations, endocrine therapy, Markov.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Breast cancer is the most common cancer among women in the
Western world [1]. The primary aim of treatment of early breast
cancer is to achieve a cure by intensive local and systemic treat-
ment [2]. Currently, themajor therapies for early breast cancer are
surgery, radiotherapy, chemotherapy, endocrine therapy, and im-
munotherapy. New technologies in cancer therapiesmay improve
patient survival and quality of life, but such improvements come
at substantial costs. Therefore, health-care financing and reim-
bursement of expensive anticancer drugs [3,4] is an often dis-
cussed topic in an era of cost containment.
Reimbursement of cancer therapy in Europe is part of the social
system, and the decisions regarding reimbursement usually are
the responsibility of the government or health-care insurance
companies. The first step in the reimbursement procedure for
drugs is the approval for market authorization in Europe by the
European Medicines Agency (www.ema.europa.eu/). A positive
benefit-risk balance of the drug is needed for this approval. Sub-
sequently, each European country applies its own assessment
* Address correspondence to: G.W.J Frederix, Department of Clinic
nstitute, Plesmanlaan 121, Amsterdam, The Netherlands 1066 CX
E-mail: g.frederix@nki.nl.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.and/or appraisal procedure for reimbursement of this new drug.
Usually therapeutic benefit is the most important consideration
for these national appraisals, but more and more pharmacoeco-
nomic evaluations are also part of the reimbursement evaluation.
A complete overview of all existing European guidelines on eco-
nomic evaluations can be found at www.ispor.org.
Currently theNational Institute forHealthandClinical Excellence
NICE) in the United Kingdom is the only institution in Europe that
inks policy decisions directly to these ICERs [5]. In this process, the
CER for each therapy is compared to a threshold value, which is
enerally accepted as having an upper limit of £20,000 and 30,000 in
ases of life-saving interventions. Other European countries use
hese outcomes at thismoment only as guidance in policy decisions
6]. Such decisionsmade by policymakers and researchers of these re-
mbursement agencies are crucial for patient groups in all countries.
herefore,decisionsshouldbebasedonsolidevidence,abstractedfrom
igh-quality studies, especiallywhen ICERs are directly linked to policy
ecisions, as in the United Kingdom. In this respect, the credibility of
ost-effectiveness studies can be decreased by an unexplained and
idevariation in ICERs, seen inrecentpharmacoeconomicevaluations.
armacology and Experimental Therapy, The Netherlands Cancer
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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fectiveness studies for endocrine therapies in early breast cancer
can be found [7,8]. Their main conclusion is that aromatase inhib-
itors are cost-effective alternatives to current or previous standard
therapies for the treatment of early breast cancer. Besides, Anne-
mans [9] published a review of methodological issues in evaluat-
ing the cost-effectiveness of aromatase inhibitors in early breast
cancer, in which he concluded that there is a need for improve-
ment regarding severalmodelingmethods applied, i.e., recurrence
rate, patient subtypes, and model calibration. Although these re-
views provide useful overviews of cost-effectiveness issues of en-
docrine therapies, none of them provide causal insight into the
relationship ofmodelingmethods and reported differences in out-
come of similar endocrine therapies. Therefore, this review fo-
cuses on cost-effectiveness outcome and the mathematical mod-
els used in economic evaluations of endocrine therapy in early
breast cancer, i.e., which therapy is intended to improve cure rate
in estrogen and/or progesterone receptor–positive disease [10].
The purpose of this systematic review is primarily to identify
published cost-effectiveness analyses and cost-utility analyses of
endocrine therapies that are recommended by the European Soci-
ety of Medical Oncology (ESMO) for the treatment of early breast
cancer. A secondary objective is to identify whether the differ-
ences in seven modeling characteristics, as described in the re-
view by Annemans [9], are related to differences in outcome of
these cost-effectiveness and cost-utility analyses.
Methods
Study design
A systematic literature review was conducted to identify peer-
reviewed full economic evaluations of endocrine treatments of
early breast cancer published in the English language between
2000 and December 2010. Only those treatments of which two or
more studies were available were included to make a comparison
regarding methods among studies possible.
Treatment recommendations for early breast cancer with en-
docrine therapy were obtained from the website of the European
Society of Medical Oncology (ESMO) [2].
Search strategy
To identify all cost-effectiveness and cost-utility analyses of early
breast cancer drugs, we explodedmedical subject headings “adju-
vant” and “breast.” We used different strategies in each database
to identify cost-effectiveness analyses. For our PubMed/MEDLINE
and additional EMBASE search, we added the exploded medical
subject heading “costs and cost analysis.” The following (short-
ened) search string was used (“adjuvant” [all fields] OR ”early” [all
fields]) OR (“primary” [all fields] AND (“breast cancer” [all fields])
AND (“cost” [all fields]) OR )“economic” [all fields]). In the National
Health Service Economic Evaluation Database, we limited the
search to “breast and cancer” to be sure that no hits were missed.
The complete search string is made available in the Appendix
found at doi:10.1016/j.val.2011.08.002. References of retrieved pub-
lications and relevant overview publications were checked to
identify additional studies.
Study selection
The abstracts and titles of the resulting hits were checked by
one author (G.F.) for the following inclusion criteria: 1) the arti-
cle was published between 2000 and 2010; 2) the article was
published in English because papers in English are accessible to
academic readers all over the world; 3) the study population
consisted of patients recommended for adjuvant treatment of
breast cancer; 4) the study focused on endocrine therapies rec-ommended by ESMO for the treatment of early breast cancer;
and 5) the focus of the study was on determining the cost-effec-
tiveness or cost-utility (as defined in Drummond et al. [11]) of
drug treatment. Studies on diagnostics, radiotherapy, or sur-
gery were excluded. Information on the ICER had to be pre-
sented or it had to be possible to calculate it from the published
data; if a study did not meet the inclusion criteria, the study was
excluded and the reason recorded. Only the first reason for ex-
clusion was recorded.
Data extraction
We developed a data extraction sheet in Excel that was dis-
cussed extensively with all authors to obtain all relevant data.
Information was extracted from each included study on author,
publication year, country of the study, comparator, perspective
of analysis, source of clinical probabilities, discount rate, time
horizon, natural units of effect (cost-effectiveness analysis),
utilities (cost-utility analysis), costs, and ICERs. The ICERs pre-
sented in the assessments were converted to the year 2010 by
using the Consumer Price Index of the country of interest [12].
Subsequently, the 2010 prices were converted to international
dollars by using the Purchase Power Parity (2009) [13], which is a
economic technique used to determine the relative values of
two currencies. Finally, international dollars were converted to
Euros by using February 2011 values.
Modeling characteristics
The included articles were assessed using the following seven
aspects (Table 1), which were selected from the review by An-
nemans [9]. These seven aspects were selected because Anne-
mans demonstrated a large variation in choice of these charac-
teristics in his review. Furthermore, it appears from several
studies that these parameters have the largest absolute impact
on the ICER [14–20].
Besides the differences in methodological characteristics,
study sponsorship might also influence the outcome. All incorpo-
rated articles were checked as to whether they were sponsored by
the manufacturer of the drug.
Methodological quality
The methodological quality of the included studies was deter-
mined using the CHEC list [21]. This list contains 19 items that
were selected in a Delphi process by 23 experts in the field of
health economics and used for the assessment of the quality of
pharmacoeconomic evaluations [22]. This checklist was origi-
nally developed for assessing economic evaluations alongside
clinical trials. To increase its relevance, we added six items for
the assessment of modeling studies. These items were retrieved
from a study published by Soto [23] and were incorporated in
our checklist after extensive discussions with all authors.
All publications were assessed independently by two or more
reviewers. After the first assessment of all publications by G.F.,
other authors (A.H., J.L.S., and J.H.M.S.) each reviewed approxi-
mately one third of all publications. Differences between review-
ers were discussed; when no agreement was reached by the two
Table 1 – Methodological aspects of interest.
1 Time horizon
2 Hazard ratio
3 Incidence of recurrence
4 Carryover effect
5 Adverse events
6 Patient subtypes
7 Cost of the interventionreviewers, a third author was consulted. The findings from the
96 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 4 – 1 0 5comparison of the results were used to determine whether it was
feasible for one reviewer to score quality with this checklist in an
accurate and consistent manner.
All articles were assessed using the following characteristics:
no details given, complete details given in text, not clearly stated
within text, references given, and not applicable.
Fig. 1 – Decision tree of included and excluded studies,
with reasons for exclusions. CE, cost-effectiveness; CU,
cost utility; NHSEED, National Health Service Economic
Evaluation Database.
Fig. 2 – Overview of time schedules and treatment duration
endocrine therapies in early breast cancer (ATAC [32], IntergroupResults
Study selection
The total PubMed search resulted in 386 hits, total National Health
Service Economic Evaluation Database search resulted in 114 hits.
In addition, we searched in 881 EMBASE hits for additional papers,
but did not identify unique articles. An initial selection of publica-
tions based on title and abstract resulted in the elimination of
studies using the exclusion criteria. This selection resulted in 32
unique papers in total (Fig. 1). Abstracts and full text of these 32
articles were screened again to determine whether the article
evaluated an original cost-effectiveness/cost-utility study of an
endocrine therapy. Reviews, editorials, posters, abstracts, and
studies that involved drugs of no interest were excluded. A total of
20 publications matched all criteria.
These 20 economic evaluations involved 5 different endo-
crine therapeutic strategies, which were all assessed more than
once. The effectiveness and safety of each endocrine strategy
were evaluated in different phase III clinical trials (Fig. 2). Each
author used clinical data available from the published trials in
mathematical modeling to calculate ICERs for their economic
evaluations.
Quality of pharmacoeconomic evaluations
As assessed based on the CHEC [21] and Soto [23] lists, amajority of
evaluations (15) included correct descriptions of the model,
model data sources, appropriately assessed costs, and determin-
istic and probabilistic sensitivity analyses. We believe that these
characteristics were the most essential characteristics of this
quality assessment. Therefore, the overall quality of pharmaco-
economic evaluations of adjuvant endocrine breast cancer thera-
pies appeared to be good. In the majority of studies, however, a
limited health-care payer perspective instead of the societal per-
spective was used, and in the discussion and conclusion section,
generalizability, and ethical questions were often lacking. The re-
sults of these assessments are provided in Table 2.
After this, all publications were analyzed for differences in
modeling methods and outcomes.
nical trials applied in the pharmacoeconomic evaluation ofof cli
Exemestane Study [33], BIG 1-98 [34], and MA-17 [42].
Table 2 – Quality assessment of cost-effectiveness studies of interest for endocrine therapy for early breast cancer.
Study
[28] [27] [24] [14] [16] [29] [30] [31] [15] [26] [25] [18] [17] [41] [40] [39] [37] [36] [35] [38]
Research question, perspective, and time horizon
1 Does a well- defined objective exist? Is it clear, explicit,
and answerable?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
2 Are competing alternatives described? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ – NC NC ✓ ✓ ✓ ✓
3 Is a societal perspective used? – – – – – – – – – – – – – – – – – – – –
4 Is it justified why the narrower perspective is valid? – – – – – – – – – – ✓ – – – – – – – – –
5 Is a lifetime horizon taken into account? – ✓ ✓ ✓ ✓ – – – ✓ – – ✓ – ✓ ✓ ✓ ✓ – ✓ ✓
6 Are reasons for another time horizon incorporated? – – – NA NA – – ✓ NA ✓ ✓ NA ✓ NA NA NA – ✓ NA NA
Type and description of the model
7 Is the type of model used in the study stated clearly? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ – ✓ ✓ ✓
8 Are details of the model given? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
9 Is the design of the model appropriate and does it include
the correct health states?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ – ✓ ✓ ✓ ✓ – ✓ ✓ ✓ ✓ ✓
Model data sources
10 Are the sources of all values credible and accurate? ✓ ✓ – ✓ NC ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ NC NC ✓ ✓ ✓ ✓
11 Are assumptions incorporated into the model clearly
stated?
✓ ✓ – ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Outcomes and probabilities
12 Are all important and relevant outcomes for each
alternative identified (LY or QALYs gained)?
✓ ✓ – ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
13 Are the probabilities that outcomes happen clearly
stated?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ – ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
14 Are all outcomes measured appropriately? ✓ ✓ – ✓ ✓ NC NC ✓ ✓ ✓ ✓ ✓ ✓ ✓ NC NC ✓ ✓ NC ✓
15 Are outcomes valued appropriately? NC ✓ – ✓ ✓ NC NC NC NC ✓ ✓ NC ✓ ✓ ✓ NC NC ✓ NC ✓
Costs
16 Are all important and relevant costs for each alternative
identified?
✓ ✓ – ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
17 Are all costs measured appropriately in physical units? – ✓ – ✓ – NC NC NC NC – ✓ NC – NC – – NC ✓ NC ✓
18 Are costs valued appropriately? – ✓ ✓ ✓ ✓ ✓ NC ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ – NC ✓
19 Are all future costs and outcomes discounted
appropriately?
– ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Incremental analysis and sensitivity analysis
20 Is an incremental analysis of cost and outcomes of
alternatives performed?
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
21 Is a one-way sensitivity analysis performed? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ –
22 Is a probabilistic sensitivity analysis performed? – ✓ ✓ ✓ ✓ – – ✓ ✓ – – ✓ ✓ ✓ ✓ ✓ ✓ – – ✓
Discussion and conclusions
23 Do the conclusions follow from the data reported? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
24 Does the study discuss the generalizability of the results
to other settings and patient/client groups?
– – ✓ – – – – ✓ ✓ – – – ✓ ✓ ✓ ✓ ✓ – ✓ –
25 Does the article indicate that there is no potential conflict
of interest of study researcher(s) and funder(s)?
– – ✓ – ✓ – – – – ✓ – – ✓ – – – – – – –
26 Are ethical and distributional issues discussed
appropriately?
– – – – – – – – – ✓ – – – – – – – – – –
Modifications and reasons of modifications made are presented in the Appendix, found at doi:10.1016/j.val.2011.08.002.
–, no details given; ✓, complete details given in text; LY, life-year; NA, not applicable; NC, not clearly stated in text, references given; QALY, quality-adjusted life-year.
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Table 3 – Overview of outcomes and modeling characteristics of endocrine economic evaluations in order of increasing cost-effectiveness.
Interventions Ref. Country LY
gained*
QALYs
gained*
Incremental
costs, €†
Cost per LY
gained, €†
Cost per
QALY
gained, €†
Time
horizon,
years
Hazard ratio Absolute
incidence of
recurrence
Carryover
effect
Adverse
events
Patient subtypes Difference in
cost of the
intervention,
€
Anastrazole vs.
tamoxifen
[28] Belgium 0.353 0.378 1397 3958 3696 20 Outcome specific Constant 5 years Yes None 2.53
[27] UK 0.350 0.360 3084 8810‡ 8566‡ 50 Outcome specific Time dependent None Yes None 2.86
[14] Brazil 0.550 NA 9929 17,920 NA Lifetime 0.74 Constant Lifetime Yes None —
[27] UK 0.250 0.260 3535 14,125§ 13,793§ 50 Outcome specific Time dependent 5 years Yes None 2.86
[14] US 0.221 0.257 4206 14,140 16,338 25 0.74 Time dependent 5 years Yes None 4.22
[16] Canada 0.194 0.218 3688 19,028 16,915 Lifetime 0.83 Time dependent 5 years Yes None 3.31
[29] Belgium NA 0.231 4314 NA 18,672 20 0.83 Constant 5 years Yes Age in sensitivity
analysis
3.54
[30] Canada NA 0.227 4110 NA 18,097 20 0.83 Constant 5 years Yes Age in sensitivity
analysis
3.05
[16] Canada 0.192 0.208 3797 19,745¶ 18,264¶ Lifetime 0.83 Time dependent 5 years Yes None 3.31
[31] Germany 0.290 0.320 6303 21,732 19,473 25 0.76 Time dependent 5 years Yes None 5.46
[15] UK 0.230 0.244 5370 23,273 21,971 25 0.74 Time dependent 5 years Yes None 4.27
[30] Canada NA 0.092 4041 NA 43,907 10 0.83 Constant 5 years Yes Age in sensitivity
analysis
3.29
[26] US 0.160 0.123 5406 32,763 61,250 20 Outcome specific Constant 5 years Yes None 4.44
[25] Spain 0.535 0.285 20,537 38,387 72,060 20 0.83 Constant None Yes None 5.32
[25] Spain 0.182 0.114 13,710 75,331 120,265 10 0.83 Constant None Yes None 5.32
Anastrazole vs.
tamoxifen 
exemestane
[30] Canada NA 0.017 2883 NA Dominated 20 0.70 Constant 5 years Yes Age in sensitivity
analysis
0.23
[29] Belgium NA 0.020 3145 NA Dominated 20 0.70 Constant 5 years Yes Age in sensitivity
analysis
0.64
[30] Canada NA 0.016 2804 NA 178,270 10 0.70 Constant 5 years Yes Age in sensitivity
analysis
0.23
Letrozole vs.
tamoxifen
[20] UK 0.510 0.520 3948 7741 7592 50 Outcome specific Time dependent 5 years Yes None 3.49
[20] UK 0.350 0.360 4504 12,869 12,477 50 Outcome specific Time dependent None Yes None 3.49
[31] Canada 0.368 0.343 5130 13,942 14,969 30 0.70 Time dependent 5 years Yes Age in sensitivity
analysis
3.10
[30] US 0.440 0.409 7525 17,220 18,409 30 0.70 Time dependent 5 years Yes Age in sensitivity
analysis
4.65
Extended
letrozole vs.
no extended
therapy
[41] UK 0.320 0.360 4728 13,345 13,189 40 Outcome specific Time dependent None Yes None 4.49
[40] Canada 0.332 0.290 4929 14,869# 16,993# Lifetime 0.48 node
negative, 0.61
node positive
Constant 5 years No 100% node-positive
patients
3.58
[40] Canada 0.267 0.236 5139 19,263** 21,796** Lifetime 0.48 node
negative, 0.61
node positive
Constant 5 years No 50% node positive
and 50% node-
negative patients
5.71
[39] US 0.320 0.338 7827 24,427 23,183 30 Outcome specific Time dependent 5 years Yes Node negative, node
positive, and age
in sensitivity
analysis
3.58
[40] Canada 0.202 0.182 5351 26,467†† 29,469†† Lifetime 0.48 node
negative, 0.61
node positive
Constant 5 years No 100% node-negative
patients
3.58
(continued on next page)
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Table 3 (continued)
Interventions Ref. Country LY
gained*
QALYs
gained*
Incremental
costs, €†
Cost per LY
gained, €†
Cost per
QALY
gained, €†
Time
horizon,
years
Hazard ratio Absolute
incidence of
recurrence
Carryover
effect
Adverse
events
Patient subtypes Difference in
cost of the
intervention,
€
Exemestane vs.
continuing
tamoxifen
[37] US 0.390 0.260 3333 8451‡‡ 12,871‡‡ 35 Outcome specific Time dependent None Yes ER positive only 4.07
[36] Canada 0.103 0.120 1849 17,995 15,477 7.5 Outcome specific Time dependent None Yes None 2.94
[37] US 0.330 0.220 3411 10,312§§ 15,584§§ 35 Outcome specific Time dependent None Yes ER positive and ER
negative
4.07
[35] Sweden 0.220 0.160 2443 11,193 15,760 Lifetime 0.69 Time dependent None Yes None 3.11
[38] Germany 0.249 0.238 3942 15,840 15,840 Lifetime Unknown Constant None Yes None —
[25] Spain 1.046 0.566 23,091 22,075 40,796 20 0.68 Constant None Yes None 6.37
[25] Spain 0.360 0.230 16,586 46,072 72,112 10 0.68 Constant None Yes None 6.37
Tamoxifen 
exemestane
vs.
tamoxifen
[29] Belgium NA 0.251 1168 NA 4650 20 0.70 Constant None Yes Age in sensitivity
analysis
4.18
[30] Canada NA 0.244 1226 NA 5034 20 0.70 Constant None Yes Age in sensitivity
analysis
3.52
[30] Canada NA 0.076 1260 NA 16,513 10 0.70 Constant None Yes Age in sensitivity
analysis
3.52
Notes: Exchange rate: 1 €  1.35 US$. Time horizon  the length of the period in which costs and outcomes will be considered. LYs gained  (LYs gained by drug of interest)  (LYs gained by
comparator). QALYs gained  (QALYs gained by drug of interest)  (QALYs gained by comparator). Incremental costs  (total costs treatment with drug of interest)  (total costs treatment with
comparator). Cost per LY (incremental costs)/(LYs gained). Cost per QALY (incremental costs)/(QALYs gained). Dominated effectiveness of treatment is lower and treatment costs are higher.
Adverse events  adverse events included in analysis.
Absolute incidence of recurrence  risk of recurrence after therapy (constant or time dependent). Carryover effect  inclusion and duration of effect after treatment cessation.
Patient subtypes  use of patient subtypes in analysis. Daily cost therapeutic  daily cost of the intervention. Daily cost comparator  daily cost of the comparator. Difference in cost of the
intervention  (daily cost of the intervention)  (daily cost of the comparator).
Unable to calculate daily cost from the article.
* LYs and QALYs gained are presented as stated in the articles.
† Original costs are converted to Euros (February 2011).
‡ Five-year carryover effect.
§ No carryover effect.
 Three-year interim analysis.
¶ Five-year interim analysis.
# 100% node-positive patients.
** 50% node-positive and 50% node-negative patients.
†† 100% node-negative patients.
‡‡ Estrogen receptor–positive and estrogen receptor unknown patients.
§§ Estrogen receptor positive only.
99
V
A
L
U
E
IN
H
E
A
L
T
H
1
5
(2
0
1
2
)
9
4
–
1
0
5
[
f
f
f
c
s
[
€
t
€
o
g
c
m
0
€
b
z
1
t
0
[
€
g
y
w
t
M
h
[
s
L
Q
g
c
s
c
m
S
Q
o
t
a
e
t
p
[
s
p
0
0
a
[
100 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 4 – 1 0 5Outcomes
Costs and outcomes of the 20 selected publications are provided in
Table 3. We identified 11 cost-effectiveness analyses of anastra-
zole compared to the, until then, standard treatment tamoxifen
[14–16,24–31]. All studies used the ATAC trial [32] to obtain tran-
sition probabilities and were performed from a health-care payer
perspective. Incremental life-years (LYs) gained ranged from 0.16
[26] to 0.550 [24], with an ICER ranging from €3,958 [28] to €75,331
25]. Incremental quality-adjusted LYs (QALYs) gained ranged
rom 0.092 [30] to 0.378 [28], with a cost per QALY gained varying
rom €3,696 [28] to €120,265 [25]. Comparable studies were per-
ormed in four 4 different countries. Two studies in Belgium cal-
ulated ICERs of €3,696 [28] and €18,672 [29] per QALY gained, two
tudies in the United States found ICERs of €61,250 [26] and €16,338
14] per QALY gained, and two studies in theUK calculated ICERs of
8,566 [27], €13,793 [27] and €18,264 [15] per QALY gained. Finally,
wo studies in Canada calculated costs of €16,915 [16], €18,264 [16],
18,294 [30], and €44,386 [30] per QALY gained, respectively.
Two analyses also compared anastrazole with a combination
f tamoxifen and exemestane [29,30]. Both studies used the Inter-
roup Exemestane Study [33] to obtain probabilities from a health-
are payer perspective. For the analysis of anastrazole versus ta-
oxifen and exemestane [29,30], QALYs gained varied between
.016 [30] and 0.02 [29]. Costs of these QALYs varied between
178,270 [30] and a dominated outcome [29].
Three pharmacoeconomic analyses of letrozole were selected
ased on our criteria [17,18,27]; all three analyses compared letro-
ole to tamoxifen and used data from the same source, i.e., the BIG
-98 trial [34]. In all three analyses, the health-care payer perspec-
ive was used. Incremental LYs gained ranged from 0.350 [27] to
.510 [27] and incremental QALYs ranged from 0.343 [17] to 0.520
27]. The additional LYs and QALYs cost ranged from €7,741 [27] to
17,220 [18] per LY and from €7,592 [27] to €18,409 [18] per QALY
ained, respectively.
The cost-effectiveness of switching to exemestane after 2 to 3
ears of therapy with tamoxifen compared to continuing tamoxifen
as determined in five selected studies [25,35–38]. All studies used
he Intergroup Exemestane Study [33], and one also used the SEER-
edicare data [37] to obtain probabilities, and two analyses used the
ealth-care payer perspective [25,36], and for two, it was unclear
35,37]; however, because only direct costs were included, we as-
umed that a health-care payer perspective was used. Incremental
Ys gained varied between 0.103 [36] and 1.046 [25] and incremental
ALYs gained varied between 0.120 [36] and 0.566 [25]. Cost of 1 LY
ained was found to vary between €8,451 [37] and €46,072 [25], and the
ost of 1 QALY gained varied between €12,871 [37] and €72,112 [25].
The outcome of the addition of tamoxifen to exemestane was
tudied in two of the selected publications [29,30]. Both analyses
ompared treatment with tamoxifen and exemestane to treat-
ent with tamoxifen alone and used the Intergroup Exemestane
tudy [33] with a health-care payer perspective. Incremental
ALYs gained varied between 0.076 [30] and 0.251 [29] and the cost
f 1 QALY gained varied between €4,650 [29] and €16,513 [30].
In addition to these pharmacoeconomic analyses of letrozole,
hree analyses of extended letrozole were selected [39–41]. All
nalyses compared letrozole (after 5 years of tamoxifen) with no
xtended adjuvant therapy by using the MA17 [42] trial to obtain
ransition probabilities. Two of these analyses used a health-care
ayer [40,41] perspective, and for one analysis, it was not stated
39]. Because only direct costs were included, however, we as-
umed that this analysis was performed from a health-care payer
erspective. Incremental LYs gained varied between 0.202 [40] and
.332 [40] and incremental QALYs gained between 0.182 [40] and
.360 [41]. Cost of 1 LY gainedwas found to be between €13,345 [41]
nd €26,467 [40], the cost of 1 QALY gained varied between €13,189
41] and €29,469 [40].Methodological differences
The following sections show the base-case methods and assump-
tions that were applied in the 20 economic analyses with regard to
the 7 selected methodological aspects (Table 3).
Time horizon
The individual studies applied a time horizon of 7.5 [36], 10 [25,30],
20 [25,26,28–30], 25 [14,15,31], 30 [17,18,39], 35 [37], 40 [41], 50 years
[27], or lifetime [16,24,35,38,40] (see Table 3 for an overview per
therapy group).
Hazard rate for recurrence
The hazard ratio for recurrence is one of the essential differ-
ences between two adjuvant therapies. Within the analyses, a
wide variation was observed in the use of the hazard ratio. The
use of hazard ratios varied from the use of a disease-free sur-
vival hazard ratio (which includes background mortality in ad-
dition to death due to breast cancer) [16–18,25,29,30,35], recur-
rence-free survival hazard ratio (does not include background
mortality and includes breast cancer recurrence and deaths due
to recorded recurrence) [14,15,24,31], and even outcome-spe-
cific hazard ratios for different types of recurrence were used
[26–28,36,39,41].
Incidence of recurrence
The majority of authors considered a time-dependent recurrence
risk and used recurrence rates, which varied over time [14–
18,24,25,27,31,35–37,39]. Several other authors applied a constant
probability of recurrence, in which the recurrence rate stayed at
the same level up to the end of the model [24,26,28–30,40]. Breast
cancer mostly recurs within the first 2 to 3 years after initiation of
therapy, with a peak at about 2 years [19,43]. For women with
strong estrogen receptor–positive or progesterone-positive tu-
mors, breast cancer often recurs after a period of 10 years after
initial treatment has stopped [44,45].
Carryover effect
In the latest updates of several trials, carryover effects (effects
of treatment that persist after treatment has been stopped)
were confirmed for several years after treatment cessation
[46,47]. Five analyses of interest did not use a carryover effect
[25,27,35,36,39,41], several others used a carryover effect of 5
years (14–18,28–31,40], and one analysis used a carryover effect
that lasts for the entire life span of the patient [24] (Table 3).
Adverse events
Sensitivity analyses have shown that the inclusion of adverse
events has a strong impact on ICERs. A wide variety of adverse
events was included in the models of interest, with fractures, ve-
nous thromboembolism, vaginal bleeding, and endometrial can-
cer as the most frequent ones. One study only included hip frac-
tures and osteoporosis [39], and another study only included
fractures [41]. Two studies did not present the adverse events in
detail [24,28], and one study did not use any adverse events in the
model [40].
Patient subtypes
One study subdivided patients into node-negative and node-pos-
itive groups [40] for base-case calculations. One other study calcu-
lated ICERs for estrogen receptor–positive or progesterone-posi-
tive patients for the analysis of exemestane versus continuing
tamoxifen [37]. All other studies did not use any patient subtypes
in their base-case analyses.
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Price differences per day between the intervention and the compar-
ator varied from €2.53 to €5.46 for anastrazole versus tamoxifen,
€0.23 to €0.64 for anastrazole versus tamoxifen  exemestane,
3.10 to €4.64 for letrozole versus tamoxifen, €3.58 to €5.71 for ex-
ended letrozole versus no extended adjuvant therapy, €2.94 to €6.37
or exemestane versus continuing tamoxifen, and €3.52 to €4.18 for
amoxifen exemestane versus tamoxifen alone (Table 3).
Discount rates could also be considered to have large impact,
ut because all countries considered in our review have guidelines
or the application of a discount rate [6], the relationship between
he results and the discount rate is driven by these country-spe-
ific requirements. Unfortunately, no undiscounted numbers
ere given in the majority of studies, and therefore the influence
f discount rates could not be analyzed in detail.
Two of all 20 incorporated articles were nonpharmaceutical
ompany-sponsored studies [26,29].
As well as the diversity seen in the modeling methods, a large
iversity was seen in the choice of health states and cycle length
sed in the Markov models. Furthermore, instead of the usual
ead-to-head comparisons, several articles compared treatments
y using indirect comparison [27,29,30,48]. These indirect compar-
sons refer to a comparison of different health-care interventions
sing data from separate studies. In addition, several studies used
ata from clinical trials [34] in which patients could switch from
ontrol to study treatment. To answer the question of what would
ave been the survival experience of two patient groups in the
bsence of a crossover, authors in the BIG 1-98 trial applied the
nverse probability of censoring weighted (IPCW) method to re-
ove the bias caused by treatment crossover [49]. Last, overall
urvival was driven by recurrence in all studies because of the
bsence of overall survival data.
Impact variation
The following sections demonstrate the possible impact of the
variation in methodological characteristics on the ICER. The im-
pact of these characteristics was obtained from sensitivity analy-
ses or base-case analyses; therefore, outcomes in these examples
were not adjusted for the current inflation rate. Differences in
inclusion of adverse events and incidence of recurrence were not
tested separately in sensitivity analyses within the evaluations of
interest; therefore, no examples are given.
Time horizon
In several selected publications, a sensitivity analysis of the time
horizon was performed that showed large effects on ICERs
[16,25,26,37]. In addition to these sensitivity analyses, several au-
thors performed base-case analyses with a 10- and 20-year time
horizon [25,30]. In the analysis by Skedgel et al. [30], ICERs varied
from €43,907 for 10 years to €18,097 per QALY gained for 20 years,
orresponding to a decrease of 59%. Lux et al. [31] showed the
mpact of the time horizon using a 10-, 15-, 20-, and 25-year time
orizon, which resulted in ICERs of, respectively, €44,676, €27,185,
22,776, and €21,069 per QALY gained.
Hazard ratio for recurrence
Skedgel et al. [29] tested the influence of the use of a disease-free
survival hazard ratio and a recurrence-free survival hazard ratio.
The analysis based on the disease-free survival hazard ratio re-
sulted in an ICER of €19,982, and the analysis based on the recur-
rence-free survival hazard ratio resulted in an ICER of €11,338,
which corresponds to a decrease of 43%.
Carryover effect
A few authors tested the influence of a carryover effect in their
sensitivity analyses and found a strong decrease in the ICER byusing a carryover effect [8,27,29,30]. For instance, the sensitivity
analysis performed by Skedgel et al. [30] showed that the inclusion
of a carryover effect results in a decrease in ICER of approximately
38%. In addition to these sensitivity analyses, a few authors in-
cluded base-case analyses with or without a carryover effect, with
ICERs varying from €13,793 per QALY gained without a carryover
effect to €8,566 per QALY gained with a carryover effect up to 5
years [27], which also corresponds to a decrease of 38% in the ICER.
Patient subtypes
Several of the selected articles provided information about patient
subtypes, for which the effect of age especially was shown in sen-
sitivity analyses [17,18,29,30,39]. A combination of node-negative
and node-positive patients had a cost of €21,796 per QALY gained,
the cohort of 100%node-negative patients had a cost of €29,469 per
QALY gained, and the cohort of 100% node-positive patients had a
cost of €16,993 perQALY gained. In the other study, costs of €15,584
for estrogen receptor–positive and €12,871 for estrogen receptor–
negative patients per QALY gained were calculated [37]. The cost-
effectiveness of letrozole therapy is more favorable in younger
postmenopausal women, with the cost varying from €12,338 for
50-year-old patients to €80,718 for 70-year-old patients [17].
Cost of the intervention
A few articles of interest included the sensitivity analyses per-
formed and showed a strong improvement in the ICERwhen using
lower costs [26,35,37]. For instance, Lundkvist et al. [35] incorpo-
rated the cost of tamoxifen and exemestane in their sensitivity
analysis. Varying the cost of exemestane to 75%of the original cost
results in a 55% decrease in the ICER compared to using 125% of
the original cost.
Sponsorship
Both nonpharmaceutical company–sponsored studies calculated
higher ICERs compared to the average outcomes of all other stud-
ies. Respectively, €18,097 (20-year analysis) [29], €43,907 (10-year
analysis) [29], and €61,250 [26] per QALY gained.
Discussion
We identified 20 publications about cost-effectiveness estimates
of endocrine therapies in early breast cancer that met our inclu-
sion criteria. These included 13 studies of anastrazole [14–16,24–
30], three of letrozole [17,18,27], 3 of extended letrozole [39–41], 5
of exemestane [25,35–37], and 2 of tamoxifen in combination with
exemestane [29,30]. In general, the quality of these analyses ap-
peared to be good, and all analyses adhered to the general guide-
lines of pharmacoeconomic evaluations. Several articles ac-
counted for all influential methodological characteristics, but we
believe that the article by Mansel et al. [15] could be identified as a
high-quality assessment. Apart from including all methodological
characteristics, this article also incorporated a short cycle length
(3 and 6 months) and used a transparent way of publishing all
assumptions and probabilities. In the analyses of interest, how-
ever, a wide variation in outcomes for several similar therapies
appeared, despite the use of the same trial data (Table 2). Hence,
the large variations in outcome must be caused by differences in
approach and modeling methods among studies.
Three analyseswith ICERs above the threshold defined byNICE
of £30,000 in the anastrazole versus tamoxifen group calculated
low numbers of LYs and QALYs gained. One analysis used time
horizons of 10 and 20 years, a hazard ratio of 0.83, a constant risk
of recurrence, and no carryover effect [25,26,30]. The other used a
time horizon of 20 years, a constant risk of recurrence, and a car-
ryover effect of 5 years [26]. As stated in pharmacoeconomic
guidelines around theworld, the time horizon of studies should be
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102 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 4 – 1 0 5long enough to capture all relevant costs and outcomes [6]. Time
orizons that are too short fail to capture the full costs and conse-
uences of chronic disease management. As a result, an underes-
imated effect of treatment was seen in analyses with a short time
orizon, especially in two analyses with a 10-year time horizon
25,30]. Because estrogen receptor–positive and progesterone re-
eptor–positive breast cancer often recurs 10 years after initial
reatment ends, a time horizon of 10 years is considered too short.
Table 4 – Summary of recommendations for cost-effectiven
Item Options (based on
review)
7 characteristics according
to Annemans [9]
Time horizon Short (10–15 years) To
Mediocre (15–25 years)
Long (25 years)
Carryover effect (effect of
treatment persists when
treatment is stopped)
Not included A
Included
Hazard ratio Disease-free survival Th
Recurrence-free survival
Outcome specific *
Incidence of recurrence Constant over time In
Time dependent
Adverse events None A
Selected
All possible
Patient subtypes/
subgroups
None Cl
Age
ER/ER
Cost of the intervention Not specified D
Specified
Additional model
characteristics
Health states A large variety of health
states were included
in the models.
Th
Cycle length 3 months Re
3–12 months
1 year
Mortality modeling Overall survival based on
recurrence
If
Indirect comparisons Yes In
1)
2)
3)
4)
5)
No
Crossover effect between
therapies
Not justified A
IPCW, inverse probability of censoring weighted.
* Hazard ratios for various metastatic sites.
† Recurrence rate varies over time with peaks at 3 to 4 and 8 to 10 yehe use of a constant risk of recurrence results in the use of a toohigh recurrence rate over several years because the majority of
recurrences in early breast cancer occur in the first 2 years after
diagnosis [19,43,50] and for estrogen receptor–positive and proges-
terone receptor–positive tumors, after a period of 10 years from
the end of the initial treatment [44,45]. Therefore, the use of a
constant probability underestimates the effect of the intervention
and overestimates the ICER. The use of no carryover effect as-
sumes that the effect of the drugs of interest is directly halted
models in adjuvant breast cancer.
Recommendations
ure all relevant costs and outcomes, it is essential to use a lifelong
horizon.
over effect is an important characteristic for several hormonal
pies. Therefore, if relevant, a carryover effect should be included in
conomic analysis.
e of recurrence is an essential characteristic for the outcome. The
rence-free survival hazard ratio should be included in the base-
analysis. When possible, the impact of other hazard ratios should
sessed in the sensitivity analysis.
n of a time-dependent incidence of recurrence is a better
sentation of the course of the disease.†
erse events that could cause death (endometrial cancer,
boembolic events, and hip fracture), are very costly events (i.e.,
fracture, vaginal bleeding, biphosphonate treatment), and have a
us impact on quality of life (endometrial cancer, thromboembolic
ts) should be included.
l effectiveness of a therapy is often different between subtypes and
roups of patients. Therefore, additional analyses of subtypes (ER/
and subgroups (age) is essential.
the large impact of therapeutic costs on the outcome, it is essential
plicitly report the cost of the intervention.
rkov model must at least include a disease-free, local recurrence,
static disease, and background mortality death state and a disease-
ed death state. Use of additional health states should be justified,
where possible, the impact on the outcome should be stated.
nces are very relevant for the outcome and can occur continuously
time, therefore, a short cycle length will be a better representation
e course of the disease. A cycle length of 3 months should be used,
h represents the time when patients are seen in a hospital. Longer
lengths should be justified.
ng-term survival data are included in the study, it is recommended
se overall survival on recurrence. Applied literature for transition
recurrence to death should be relevant for the studied setting.
t comparisons are feasible, but should be justified and checked for
llowing characteristics:
fication for indirect comparison
tification and selection of clinical trial and/or meta-analyses
r description of methods provided
acteristics of the included trials that may cause heterogeneity are
ented
ils on how heterogeneity and adjustment for effect modifiers (i.e.,
nt characteristics, measurement of outcomes, and protocol
irements) among trials are handled are provided.
al assessment of clinical trial data is needed to assess whether
al trial data are crossover free. The IPCW method is recommended
tain crossover-free data. Other methods could be appropriate but
ld be justified in the article.ess
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103V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 9 4 – 1 0 5treatment. In combination with a high incremental cost, effect-
underestimatingmodelingmethods lead to the calculation of high
ICERs. One 20-year analysis had an unexplained high number of
LYs andQALYs gained [25,28]. Thiswas despite the use of a 20-year
time horizon, a constant risk of recurrence, and no carryover ef-
fect. This analysis also calculated very high ICERs, which was
caused by the high country-specific costs. One other analysis cal-
culated very low ICERs [28], which was caused by the low incre-
ental costs. These low incremental costs were due to the fact
hat costs were incurred solely during the first 5 years in this anal-
sis. The large incremental costs in the other analysis were unex-
lained. The calculations based on the Brazilian situation [24] re-
ulted in a very high number of LYs gained compared to outcomes
n other studies. This could be related to the combination of mod-
ling characteristics within this analysis. The Brazilian study in-
luded a lifetime time horizon, a recurrence-free survival hazard
atio of 0.74, and inclusion of a lifetime benefit of anastrazole. All
hree characteristics were shown to cause an increase in LYs
ained and a decrease in ICERs in several sensitivity analyses.
Two studies performed from a Belgian perspective calculated a
.5-fold difference in the number of QALYs gained. The incremen-
al cost difference in both studies could be explained by the differ-
nce in costs of the intervention. The only difference in the pre-
efined seven characteristics was seen in the inclusion of specific
azard ratios for local and distant recurrence by one study. How-
ver, because one analysis [29] based the amount of local and dis-
ant recurrences on the proportion of both types in the ATAC trial,
hey also incorporated different chances for both recurrences.
herefore, this could not be the cause of the large discrepancy in
ALYs gained. Other modeling differences between both studies
ust be present that are related to this discrepancy in outcome.
oth U.S. studies calculated a twofold difference in QALYs gained,
hich could be caused by underestimation of the effect of anas-
razole in one study using a constant probability [26] and a hazard
atio for disease free survival (DSF) (0.83) compared to outcome-
pecific hazard ratios in the other analysis. Among the UK studies,
differencewas seenwhen the carryover effect was included. Due
o this carryover effect, one study calculated more QALYs gained,
nd therefore an improved ICER was seen. The other difference
etween the UK studieswas caused by the difference in incremen-
al costs, possibly due to the difference in medication price.
A short time horizon and a constant probability were also used
n the analysis that revealed a cost of €178,270 per QALY gained for
nastrazole versus tamoxifen exemestane [30]. The low number
f QALYs gained in this analysis, however, was caused by the
mall difference in effect of both therapies. The only varying out-
ome between the analyses of letrozole versus tamoxifen was
aused by the use of a carryover effect. When introducing a carry-
ver effect up to 5 years, the number of LYs and QALYs gained
ncreased, resulting in a more favorable ICER [27].
In contrast to these outcomes, the high ICER seen in the anal-
sis of extended letrozole versus no extended therapy was caused
y differences in effect among patient cohorts. The selection and
ffectiveness of adjuvant systemic treatment rely heavily on path-
logical nodal status, tumor grade, tumor size, and estrogen re-
eptor status [2]. As a result, therapy for some women may prove
ery effective and cost-effective, and for others, no significant pos-
tive effects are seen. In this analysis, extended letrozole is less
ffective in node-negative patients. Because of that, a less favor-
ble cost-effectiveness ratio was calculated.
Thehighest ICERs in the exemestane versus continuing tamox-
fen group [25] are above all caused by the large incremental costs.
oth analyses (10- and 20-year time horizon) calculated high num-
ers of LYs and QALYs gained compared to other studies, which is
emarkable because of the use of a short time horizon, constant
isk of recurrence, and no carryover effect. No explanations for the
igh incremental costs and high number of LYs and QALYs gainedere given in this publication. Differences between both U.S.-
ased studies are related to the difference in effect of interven-
ions between both patient cohorts. Exemestane was more effec-
ive in the cohort with estrogen receptor–positive patients only,
hich decreased the ICER.
Finally, the only difference seen between the analyses of ta-
oxifen  exemestane versus tamoxifen was the low number of
ALYs gained when using a 10-year time horizon compared to
oth 20-year time horizons. The differences in ICERs between the
tudies performed in Canada and Belgium is related to differences
etween jurisdictions because the same model was used for both
nalyses.
Furthermore, it was remarkable to see that both nonpharma-
eutical company–sponsored analyses calculated lower numbers
f QALYs and LYs gained and indirectly a higher ICER in the anas-
razole versus tamoxifen group. These outcomes confirm the con-
lusionsmade by Jang et al. [51] that economic evaluations funded
y a pharmaceutical company are less likely to reach unfavorable
onclusions, but it must be kept in mind that in this case it only
ccurred in two analyses and that nonpharmaceutical company–
ponsored studies also calculated high ICERs.
Limitations
There are some limitations of this systematic review that must be
addressed. First, this review included only fully published studies
between 2000 and December 2010 in the English language, which
may have omitted some earlier cost-effectiveness analyses. Sec-
ond, there are several factors that limit the transferability of study
results to other countries [52,53]. We only converted foreign cur-
rencies to Euros with help of current quotations and inflation
rates. Therefore, we did not take into account several important
transferability factors, for example, prices, practice variation, life
expectancy, and disease spread [54]. As well as differences in
methodology, these factorsmay have caused discrepancies in out-
comes in the studies of interest. Last, we did not use the checklist
made by Philips et al. We believe this checklist is too comprehen-
sive for our quality assessment. Therefore, we used the combina-
tion of CHEC [21] and Soto [23] lists to assess the quality of the
included articles.
Conclusions
Based on these findings, we conclude that there is awide variation
in the calculated ICERs of endocrine therapy analyses between
and even within several countries, despite the use of similar clin-
ical trials for data input. Apart from cultural differences between
countries, several large differences in reported ICERs are caused by
the choice of modeling methods. This is especially demonstrated
in the large differences in outcomes of similar countries in which
transferability characteristics do not play any role.
To improve the comparability of future pharmacoeconomic
evaluations of early breast cancer and to decrease the diversity in
modeling choices, an optimal model with standardized, clinically
relevant, modeling methods is necessary. A standard model was
already advocated by Annemans [9] in his publication 3 years ago,
but in the literature, not much progression on standard models
was made afterward.
Any standard model should reflect a coherent theory and the
underlying biological process of a disease [55]. Regarding the seven
characteristics analyzed, to a large extent, we confirmed the find-
ings of Annemans [9]: a standard model for the assessment of
breast cancer treatment should at least take into account the fol-
lowing characteristics: a lifetime time horizon to capture all rele-
vant costs and outcomes; a hazard ratio based on recurrence-free
survival; inclusion of a time-dependent risk of recurrence, which
has a better representation of the course of the disease; the use of
s
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patient subgroups in sensitivity analysis (age, estrogen receptor
positive, estrogen receptor negative). We specified and extended
the recommendations made by Annemans regarding adverse
events and costs of the intervention, not only accounting for ad-
verse events in detail, but more specifically those adverse events
should be included that could cause death (endometrial cancer,
thromboembolic events, and hip fracture), are very costly (i.e.,
spine fracture, vaginal bleeding, biphosphonate treatment), or
have a serious impact on the quality of life (endometrial cancer,
thromboembolic events, andhip fracture). Cost of the intervention
must be transparently specified, and the impact should be tested
in the sensitivity analysis. In addition to the conclusions regarding
the seven methodological characteristics, we also recommend
that both deterministic and probabilistic sensitivity analysesmust
be included in the evaluation (Table 4).
Furthermore, because several other differences in model re-
sults could not be related to the seven characteristics assessed, we
additionallymake recommendations regarding standardization of
health states, cycle length, and other important assumptions.
More specifically, the Markov model must at least include a dis-
ease-free, local recurrence, metastatic disease, background mor-
tality death state and a disease-related death state. Use of addi-
tional health states should be justified, and where possible the
impact on the outcome should be stated. Cycle length should be as
short as possible to adequately represent the chronic disease
pathway in which series of events occur through time. In discrete
models, a cycle length of 3 months is recommended; longer cycle
lengths should be justified. Overall survival should be driven by
recurrence, and, where possible, this should be validatedwithma-
ture overall survival data. Furthermore, in the absence of head-to-
head trials, adjusted indirect comparisons, as performed by Kar-
non et al. [27] are possible, but these have to be performed with
ome restraint because empirical evidence indicates that results
f adjusted indirect comparisons are usually, but not always, sim-
lar to those of direct comparison trials [56]. Therefore, outcomes
should be interpreted cautiously, and economic evaluations using
adjusted indirect comparisons should be checked for justification,
clear descriptions of methods, whether they present characteris-
tics of the included trials, and provide details on how heterogene-
ity and adjustment for effect modifiers (i.e., patient characteris-
tics, measurement of outcomes, and protocol requirements)
among trials is handled. Last, in our opinion, economic models
need crossover-free data that are not biased by a crossover design
to calculate cost-effectiveness. Treatment crossover from one to
another therapy is often necessary on ethical grounds, but it
leaves the scientific community with an uncertainty about
whether the therapy does offer a survival advantage. We recom-
mend that authors of economic evaluations have a critical assess-
ment of whether clinical trial data are crossover free and how this
crossover-free data are generated. The IPCW method is recom-
mended because it can provide important additional evidence to
guide treatment choices [57]. Othermethods could be appropriate,
but should be justified.
In addition to all these methodological characteristics, deter-
ministic and probabilistic sensitivity analysesmust be included in
the evaluation, and, where possible, all characteristics assessed in
this review should be tested within these sensitivity analyses.
In this review,we only includedMarkovmodels in our analysis,
and therefore models based on discrete event simulation (DES)
were omitted. In a recent article Caro et al. [58] recommended that
DES is the preferred option in health economics. Although this
was recommended,Markovmodels do generate reliable outcomes
in the assessment of the cost-effectiveness of the adjuvant treat-
ment of breast cancer and do not need huge amounts of individual
data. Therefore, Markov models are well suited and a valid option
for economic evaluations of adjuvant breast cancer therapies.These conclusions confirm, specify, and extend the conclu-
sions previouslymade by Annemans [9]. By suggesting the use of a
standardized format, future pharmacoeconomic evaluations of
breast cancer therapies will be more consistent and only depend
on country-related differences. Therefore, these transparent and
standardizedmodels could be used by decisionmakers all over the
world, which will increase the usefulness, credibility, and compa-
rability and will decrease the possible influence of study sponsor-
ship of cost-effectiveness outcomes.
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